These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37721443)

  • 1. Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.
    Peng X; Shi Y; Zhang B; Xu C; Lang J
    J Med Virol; 2023 Sep; 95(9):e29084. PubMed ID: 37721443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma.
    Peng X; Wu H; Zhang B; Xu C; Lang J
    Curr Cancer Drug Targets; 2024; 24(4):425-444. PubMed ID: 37592781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
    Yu X; Chen P; Yi W; Ruan W; Xiong X
    Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
    Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
    Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
    Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
    Front Immunol; 2022; 13():862527. PubMed ID: 35493471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study.
    Lee YC; Wang JH; Chen CH; Hung CH; Lo KC; Yen YH; Kee KM; Hu TH; Lu SN; Kuo YH
    Kaohsiung J Med Sci; 2021 Oct; 37(10):894-902. PubMed ID: 34166565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
    Chen J; Chen X; Li T; Wang L; Lin G
    Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis.
    Tang Y; Zhang Y; Hu X
    Biomed Res Int; 2020; 2020():4251761. PubMed ID: 33376723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma.
    Cho SH; Pak K; Jeong DC; Han ME; Oh SO; Kim YH
    J Cell Biochem; 2019 Mar; 120(3):4140-4146. PubMed ID: 30260026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential association of STAT3 and HK-II expression in hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.
    Li M; Wang W; Jin R; Zhang T; Li N; Han Q; Wei P; Liu Z
    J Med Virol; 2016 Sep; 88(9):1552-9. PubMed ID: 26889748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.
    Yuan J; Liu Z; Wu Z; Yang J; Yang J
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109411. PubMed ID: 36461603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of viral protein interaction networks in Hepatitis B virus and Hepatitis C virus infected HCC.
    Yuan W; Huang T; Yu J; Zeng L; Lian B; He Q; Li Y; Zhang X; Zhou F; Xie L
    Biochim Biophys Acta; 2014 Jan; 1844(1 Pt B):271-9. PubMed ID: 23774196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
    Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
    Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel tumor immunotherapy-related signature for risk stratification, prognosis prediction, and immune status in hepatocellular carcinoma.
    Sun J; Xi L; Zhang D; Gao F; Wang L; Yang G
    Sci Rep; 2023 Oct; 13(1):18709. PubMed ID: 37907783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma.
    Shi Y; Huang G; Jiang F; Zhu J; Xu Q; Fang H; Lan S; Pan Z; Jian H; Li L; Zhang Y
    Front Immunol; 2022; 13():1070593. PubMed ID: 36544763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
    Marotta F; Vangieri B; Cecere A; Gattoni A
    Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.